##HariKiranChereddi
Explore articles tagged with #HariKiranChereddi
Can Asset-Light Manufacturing Make Pharma Capacity Expansion Faster, More Flexible & Scalable? | Siliconindia
Hari Kiran Chereddi, Founder, MD & CEO, HRV Pharma, explores how asset-light manufacturing can help pharmaceutical companies build greater flexibility, scalability and efficiency into their manufacturing strategies.
India’s Race for the CDMO Crown | Express Pharma
HRV Pharma Founder, MD & CEO Hari Kiran Chereddi shares insights in Express Pharma on India’s opportunity to become a strategic global CDMO partner through specialised capabilities, regulatory strength, scientific expertise and reliable execution.
HRV Pharma Bets ₹150 Crore on Peptides & High-Potency Oncology APIs | Mint
HRV Pharma is investing around ₹150 crore in peptides and high-potency oncology APIs, expanding specialised manufacturing capabilities through an asset-light model and strategic manufacturing partnerships.
Why Pharma Needs Smarter Decision-Making, Not Just More Digital Systems
CEO Hari Kiran and CIO Sowjanya Varma in Express Pharma on why pharma’s next advantage lies in reasoning rather than more systems - and how RIKO™ shifts compliance from retrospective to predictive.
Building the Next Pipeline of Specialty APIs
HRV Pharma and Haleos Labs have entered into a multi-year strategic partnership to accelerate the development and GMP manufacturing of specialty APIs for regulated and semi-regulated markets.
Centre to Require Pharma to Distinguish Biologics from Synthetics | Mint
India’s proposed amendments to the Drugs Rules, 1945 could require pharmaceutical companies to clearly distinguish biological medicines from synthetic drugs, with implications for classification, traceability, quality and regulatory oversight.
India’s Pharma Industry Goes Digital
Digital transformation is reshaping pharmaceutical manufacturing in India, with technologies such as MES, electronic batch records, LIMS, digital twins, predictive analytics and AI helping strengthen compliance, data integrity and operational efficiency.
The New Growth Blueprint for APIs | BW Healthcare World
The API industry is rethinking how manufacturing capacity and supply chains are structured, with manufacturing networks offering a more resilient approach through qualified partners, regulatory ownership and greater visibility.
HRV Pharma Introduces RIKO™, India’s First AI-Native Pharmaceutical Operating System
RIKO™ is a self-learning reasoning engine built on seven years of proprietary pharmaceutical decisions across 50+ GMP-certified partners in 55 countries.
₹400+ Crore Pharma Business Without a Factory
Business Standard explores HRV Pharma’s asset-light model, which combines regulatory assets, drug master files and customer relationships with a network of 53 manufacturing partners to build pharmaceutical scale without owning manufacturing facilities.
From Manufacturing to “Drug Visas”: How HRV Pharma Is Redefining Pharma Value Creation
HRV Pharma is redefining pharma economics by turning regulatory filings (DMFs) into scalable global assets—shifting value from manufacturing to compliance and market access.
Why the Future of Drug Development Begins Before Manufacturing
HRV Pharma CEO Hari Kiran Chereddi explains why drug development success is now determined before manufacturing, driven by data, predictive analytics, and strategic decision-making.
Future of Pharma: From Factories to Platform-Driven Models
HRV Pharma CEO Hari Kiran Chereddi shares insights on how platform-driven models are transforming pharma from factory-led systems to intelligent, network-based ecosystems.
HRV Pharma Partners with Shodhana Laboratories to Accelerate Next-Gen API Development
HRV Pharma partners with Shodhana Laboratories to accelerate next-generation API development, combining AI-enabled virtual manufacturing with precision chemistry and global regulatory execution.
How HRV Pharma’s Virtual Model Helps Solve America’s Drug Shortage Crisis
HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.
HRV Pharma Redefines India’s Bulk Drug Business with a Virtual Pharma Model
Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.
Indian Biosimilars on the Global Stage: HRV Pharma CEO's Insights in Express Pharma
India's rise in biosimilars & biologics. Full clipping + insights included.